Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Simple Blood Draw Helps Diagnose Lung Cancer 10 Times Faster

By LabMedica International staff writers
Posted on 04 Oct 2024

Once dismissed as cellular waste, exosomes—tiny vesicles released by cells containing proteins, DNA, or RNA fragments—have emerged as vital players in cell-to-cell communication over the past decade. More...

While exosomes from healthy cells carry important signals throughout the body, those from cancer cells can facilitate tumor spread by preparing tissues to receive tumor cells before they arrive. Exosomes carry proteins both inside and on their surfaces, and these surface proteins are often chiral, meaning they have a right- or left-handed twist, which influences how they interact with light. In cancer exosomes, these surface proteins are frequently mutated, meaning the protein's molecular structure has been altered by genetic changes. Such mutations subtly affect the protein’s shape, which in turn shifts its chirality. These alterations can be detected by analyzing how the proteins interact with circularly polarized light, which can "match" the twist of the proteins. When the twist aligns, a strong signal is returned to a light detector. However, these light signals are usually weak and difficult to interpret and detecting exosomes involves extracting them from blood samples, which is challenging because of their tiny size, ranging from just 30 to 200 nanometers.

Researchers at University of Michigan (Ann Arbor, MI, USA) have now developed a microchip capable of capturing exosomes from blood plasma to detect lung cancer. This new diagnostic method, which uses a simple blood draw, is 10 times faster and 14 times more sensitive than previous approaches, according to the research team. To identify exosomes, the team designed gold nanoparticles in the shape of twisted disks, adapted to capture exosomes within a central cavity. These cavities are tailored to perfectly match the size, shape, and surface chemistry of the exosomes, allowing for reliable capture. With a right-handed twist, the nanoparticles resonate strongly with right-twisting light but reflect little signal when exposed to left-twisting light—a phenomenon known as circular dichroism. Once the exosomes are trapped in the cavities, the proteins they carry can either amplify or diminish the return signal based on their shape.

The gold nanoparticle cavities, arranged along the tiny channels of a microfluidic chip, successfully captured exosomes from blood plasma and differentiated between samples from healthy individuals and those with lung cancer, as reported in the journal Matter. The microfluidic chips, called CDEXO chips (Circular Dichroism detection of EXOsomes), could also potentially distinguish specific lung cancer mutations, aiding doctors in tailoring treatments to target the most prevalent mutations as they evolve. The researchers envision the CDEXO chip initially being used alongside traditional diagnostic methods, with the potential to expand its use to screen for other cancers, improving early detection efforts as trust in the technology grows.

"As a next step, we want to look at most known solid tumor mutated proteins to understand how their spectral signatures are different,” said Sunitha Nagrath, U-M professor of chemical and biomedical engineering and co-corresponding author of the study. “From here, we can push the technology to further increase those spectral differences to distinguish between proteins."


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
New
Next-Generation Sequencing Platform
AXELIOS 1 Platform
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.